April 10th 2024
Bhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.
January 25th 2024
Bhagirathbhai Dholaria, MBBS, discusses the ongoing evaluation of noncovalent BTK inhibitors in patients with chronic lymphocytic leukemia.
August 16th 2023
Bhagirathbhai Dholaria, MBBS, discusses next steps for investigating subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma based on data from the phase 1 TRIMM-2 trial.
June 12th 2023
Bhagirathbhai Dholaria, MBBS, discusses additional 10-month follow-up data from the phase 1 TRIMM-2 trial of subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma.
October 29th 2021
Bhagirathbhai Dholaria, MBBS, discusses patient characteristics in the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.
September 30th 2021
Bhagirathbhai Dholaria, MBBS, discusses the rationale for the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.